acteria and archaea can protect themselves against mobile genetic elements and viruses, including bacteriophages, using CRISPR-Cas adaptive immunity . When challenged by a mobile genetic element, bacteria deploy CRISPR-associated (Cas) nucleases guided by an RNA 2,3 to base-pair with the target and mediate target interference to provide immunity against reinfection [3] [4] [5] . Although bacteriophages can undergo rapid mutation and selection to avoid Cas-effector targeting, genetic variation alone is insufficient to escape the potent programmability of bacterial CRISPRCas adaptive immunity 6 . To effectively evade CRISPR systems, bacteriophages have evolved protein-based inhibitors-Acrs 7-9 -that inactivate RNA-guided Cas nucleases 10,11 and enable phage replication 12, 13 . In the case of CRISPR-Cas9 (ref.
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acteria and archaea can protect themselves against mobile genetic elements and viruses, including bacteriophages, using CRISPR-Cas adaptive immunity 1 . When challenged by a mobile genetic element, bacteria deploy CRISPR-associated (Cas) nucleases guided by an RNA 2, 3 to base-pair with the target and mediate target interference to provide immunity against reinfection [3] [4] [5] . Although bacteriophages can undergo rapid mutation and selection to avoid Cas-effector targeting, genetic variation alone is insufficient to escape the potent programmability of bacterial CRISPRCas adaptive immunity 6 . To effectively evade CRISPR systems, bacteriophages have evolved protein-based inhibitors-Acrs [7] [8] [9] that inactivate RNA-guided Cas nucleases 10, 11 and enable phage replication 12, 13 . In the case of CRISPR-Cas9 (ref. 14 ), such inhibitory Acrs can prevent DNA cutting by blocking dsDNA binding [15] [16] [17] , promoting Cas9 dimerization 17 or preventing target DNA cleavage 17 . Recently, Acrs were discovered that inhibit the activities of the type V-A DNA-targeting CRISPR-Cas12a system 18, 19 . These type V-A Acrs (AcrVAs) that inhibit Cas12a might be expected to differ in mechanism, given that Cas12a has a structure 20, 21 and DNAcleavage pathway distinct from that of Cas9 (ref. 22 ). After expression of the CRISPR array and Cas proteins, Cas12a catalyzes precursor CRISPR-RNA (pre-crRNA) processing to form a Cas12a-crRNA complex (or ribonucleoprotein, RNP) 23, 24 . Unlike the commonly used Streptococcus pyogenes (Sp) Cas9, which utilizes two nuclease domains (HNH and RuvC) to cut dsDNA with single-turnover kinetics 25, 26 , Cas12a possesses a single nuclease domain (RuvC) that is activated following a crRNA targeting sequence (or spacer) binding to a complementary single-stranded DNA (ssDNA) or dsDNA target molecule 23, 27 . Furthermore, the Cas12a RuvC domain catalyzes both single-turnover target DNA cutting (cis-cleavage) and multiple-turnover non-target ssDNA cutting (trans-cleavage) 27 . To determine the mechanistic basis for Cas12a inhibition, we biochemically assayed inhibition by AcrVA1, AcrVA4 and AcrVA5 on a panel of Cas12a orthologs. While biochemical experiments revealed that no AcrVA was capable of competitively inhibiting the RuvC nuclease, each AcrVA was able to robustly target dsDNA cleavage and, to some extent, target ssDNA cleavage. Further biochemical analysis revealed that each AcrVA blocked dsDNA binding, but only AcrVA4 dimerized Cas12a and, at high concentrations, outcompeted dsDNA bound to catalytically dead LbCas12a. Finally, we demonstrate that AcrVA1 triggers multiple-turnover endoribonucleolytic cleavage of a Cas12a-bound crRNA to truncate the spacer sequence and permanently inactivate the complex. Together these data provide insights into the mechanisms of AcrVAs, shedding light on the vulnerabilities of Cas12a and the evolutionary arms race between bacteriophages and their host bacteria.
whereas AcrVA4 and AcrVA5 were effective against Moraxella bovoculi (Mb) Cas12a and LbCas12a but not Acidaminococcus sp. (As) Cas12a (Fig. 1c) , consistent with plasmid cleavage data 18 . The pattern of inhibition was generally the same for Cas12a-mediated ssDNA cleavage, but activity was not completely abolished by any inhibitor ( Fig. 1d and Supplementary Fig. 3a-c) . Collectively, these data indicated that ArcVA1 was a broad-spectrum inhibitor of Cas12a-catalyzed cis-DNA cleavage, whereas AcrVA4 and AcrVA5 inhibited cis-DNA cleavage catalyzed by MbCas12a and LbCas12a.
AcrVAs block dsDNA binding and AcrVA4 dimerizes Cas12a. We next tested whether AcrVAs affect DNA binding to Cas12a, the ratelimiting step of targeting by Cas12a 28 (Fig. 1a) . To test this, we assayed the binding of radiolabeled DNA to catalytically dead LbCas12a (dLbCas12a) by electrophoretic mobility-shift assay (EMSA). The dLbCas12a-crRNA complex was formed before the separate addition of each AcrVA and incubation with dsDNA, revealing that AcrVAs abolished dsDNA binding (Fig. 2a) while ssDNA binding was perturbed to a lesser extent ( Supplementary Fig. 4a,b) . Notably, we observed a slow-mobility species representing the DNAbound dLbCas12a-crRNA complex in the presence of AcrVA4 ( Supplementary Fig. 5a ), hinting at a possible multimeric assembly reminiscent of inhibitor-induced Neisseria meningitidis (Nme) Cas9 dimerization 17 . To test this possibility, we assessed the solution oligomeric state of each AcrVA and when mixed with LbCas12a-crRNA ( Fig. 2b and Supplementary Fig. 5b,c) . While AcrVA1 and AcrVA5 appeared monomeric ( Supplementary Fig. 5b,c) , AcrVA4 appeared dimeric before complexing with Cas12a (Fig. 2b) . Although neither AcrVA1 nor AcrVA5 triggered a substantial change in estimated molecular weight when complexed with LbCas12a-crRNA ( Supplementary Fig. 5b,c) , mixing AcrVA4 with LbCas12a-crRNA produced two higher-molecular weight species (Fig. 2b) . Using light scattering, we estimated the mass of these species to be 349 kDa and 214 kDa, consistent with a dimeric LbCas12a-crRNA-AcrVA4 complex and a monomeric LbCas12a-crRNA bound to a dimer of AcrVA4, respectively. To directly visualize the dimerization of LbCas12a-crRNA with AcrVA4, we analyzed gel filtration-purified fractions by negative-stain electron microscopy, revealing a distribution of particles including a symmetrical complex of LbCas12a-crRNA dimers ( Fig. 2c and Supplementary Fig. 5d ). Taken together, these results demonstrated that AcrVAs block dsDNA binding to Cas12a and that the mechanism for AcrVA4 involves dimerization of the LbCas12a-crRNA complex.
AcrVA4 can dislodge dsDNA bound to dCas12a. We next wondered whether any AcrVA was capable of disrupting dsDNAbound complexes of Cas12a-crRNA, a mechanism that may have evolved to disable an activated and trans-cleaving Cas12a (Fig. 1a) . To test this possibility, we attempted to displace dsDNA from a ternary complex of dLbCas12a-crRNA bound to radiolabeled dsDNA with the addition of excess AcrVA1, AcrVA4, AcrVA5 or unlabeled dsDNA and visualized the complexes by EMSA. At high concentrations, AcrVA4 triggered the release of dsDNA bound to dLbCas12a, whereas little dsDNA release occurred in the presence of AcrVA1, AcrVA5 or unlabeled dsDNA competitor ( Fig. 3a and Supplementary Fig. 6a ). In contrast, a stoichiometric excess of any AcrVA or ssDNA competitor had no effect on dLbCas12a-crRNA bound to radiolabeled ssDNA ( Supplementary Fig. 6b ). These data suggest that, at high concentrations, AcrVA4 can dislodge dsDNA after it has formed an R-loop interaction with Cas12a. Depletion or addition of ATP had no effect on dsDNA displacement from dLbCas12a-crRNA complexes by AcrVA4, suggesting an ATPindependent process (Supplementary Fig. 6c ). AcrVA4 did not trigger release of ssDNA bound to dLbCas12a-crRNA, suggesting that the non-target strand (NTS) of the DNA (the strand not base-paired to the crRNA) might be required to drive re-annealing with the target strand. In support of this possibility, addition of the NTS ssDNA molecule to the dLbCas12a-crRNA-TS DNA complex led to target strand DNA displacement in the presence of AcrVA4; a non-complementary ssDNA used in a similar experiment had no effect ( Supplementary Fig. 7a ). Consistent with target strand DNA release requiring base-pairing to a complementary NTS strand, AcrVA4 was unable to drive DNA release from dLbCas12a-crRNA bound to a dsDNA substrate containing mismatched nucleotides along all or some of the 20 nt NTS ( Supplementary Fig. 7b,c) .
The preceding experiments were conducted using catalytically inactive dLbCas12a, which prevents cutting of bound DNA and hence dLbCas12a remains associated with an intact dsDNA molecule. Given that catalytically active LbCas12a would cut and release the protospacer-adjacent motif (PAM) distal dsDNA fragment after the formation of an R-loop interaction 29 , we reasoned that this release might prevent AcrVA4 from displacing the PAM proximal dsDNA bound to the crRNA (Fig. 1a) . To test this possibility, we incubated wild-type LbCas12a-crRNA with a dsDNA substrate followed by the addition of AcrVA4 and analysis of the resulting samples by EMSA (Fig. 3b) . In contrast to dLbCas12a ( Fig. 3a and Supplementary Fig. 7d ), AcrVA4 had no effect on DNA bound by wild-type LbCas12a (Fig. 3b) . Collectively, these data demonstrated that AcrVA4 can dislodge dsDNA bound to catalytically dead but not active Cas12a, presumably due to a shift in binding equilibrium that favors dsDNA strand re-annealing.
AcrVA1 triggers endoribonucleolytic truncation of a Cas12a-bound crRNA. We next explored whether any AcrVA might prevent target DNA binding by disruption of the Cas12a-crRNA complex (Fig. 1a) . To test this possibility, we incubated Cas12a orthologs with each AcrVA individually before adding radiolabeled RNA to probe crRNA integrity, the efficacy of pre-crRNA processing and the affinity of Cas12a for mature crRNA. We were surprised to observe that AcrVA1 induced rapid 3′-end truncation of both mature and pre-crRNA in the presence of any Cas12a ortholog ( Fig. 4a and Supplementary Fig. 8a ). In these experiments, neither binding to mature crRNA nor pre-crRNA processing was affected ( Fig. 4b and Supplementary Fig. 8a ). Notably, AcrVA1 had no effect on the integrity of mature or pre-crRNA in the absence of Cas12a, and neither AcrVA4 nor AcrVA5 had any effect on crRNA in the absence or the presence of Cas12a (Fig. 4a,b and Supplementary Fig. 8a,b) . Pre-assembly of Cas12a and crRNA forms the Cas12a-crRNA complex, which was also susceptible to AcrVA1-mediated crRNA 3′-end truncation ( Supplementary Fig. 8b ). However, pre-assembly of an activated Cas12a-crRNA complex with the addition of complementary ssDNA or dsDNA prevented AcrVA1-mediated crRNA truncation ( Supplementary Fig. 8c ). Furthermore, AcrVA1-mediated crRNA truncation was specific for a crRNA bound by Cas12a regardless of spacer sequence ( Supplementary Fig. 9a ) or lengths that support Cas12a DNA-targeting 23, 27 ( Supplementary Fig. 9b ), and without any detectable non-specific ribonuclease activity ( Supplementary Fig. 9c ). Taken together, the above data indicated that AcrVA1 triggers specific crRNA truncation on an assembled Cas12a-crRNA complex.
Interestingly, AcrVA1 is not predicted to be a nuclease 18, 19 nor does it have detectable RNA cleavage activity in the absence of a Cas12a-crRNA complex ( Fig. 4a and Supplementary Fig. 9a-c) . To assess the mechanism of AcrVA1-mediated RNase activity, we mapped the scissile phosphates to positions five to eight within the crRNA spacer, with some plasticity in position dependent on the Cas12a ortholog ( Fig. 4c and and Supplementary Fig. 9d ). The activity is that of an endoribonuclease where catalysis generates an intact 3′ fragment of the crRNA that is released by Cas12a after AcrVA1-triggered truncation ( Supplementary Fig. 9e,f) . To identify the nuclease center responsible for crRNA truncation, we targeted the known nuclease domains in Cas12a for mutagenesis, the RuvC or pre-crRNA processing nuclease, and observed that mutation of either did not prevent AcrVA1-triggered spacer truncation ( Fig. 4c and Supplementary Fig. 9d ). We next assayed the metal ion dependency of the nuclease by supplementation with MgCl 2 or EDTA, and observed that AcrVA1-triggered spacer truncation was not dependent on divalent cations ( Supplementary Fig. 9g ). Consistent with this, we determined the end-group chemistry of the 5′-radiolabeled crRNA fragment with T4 polynucleotide kinase (PNK) treatment, which resulted in an upward shift in polyacrylamide gel migration, indicating that the 5′ fragment generated had a 3′ phosphate at its terminus (Fig. 4d) . Taken together, these data demonstrated that AcrVA1 triggers metal ionindependent endoribonucleolytic cleavage of the targeting portion of the crRNA, which then dissociates to render the complex rudderless with respect to DNA targeting (Fig. 4e ).
AcrVA1 is a multiple-turnover inhibitor and competes with AcrVA5. AcrVA1 stands out among the known Cas12a and Cas9 inhibitors as a highly effective and broad-spectrum inhibitor of RNA-guided dsDNA targeting by Cas12a
18
. Given its unique enzymatic activity, we wondered whether the potency of AcrVA1 inhibition might be attributed to multiple-turnover kinetics. To test this, we incubated a range of AcrVA1 concentrations with a fixed concentration of Cas12a-crRNA complex and in all cases observed that ~95% of crRNAs were truncated, even at sub-stoichiometric concentrations of AcrVA1 (Fig. 5a) . Thus, AcrVA1 activity is multiple turnover where cleavage of a crRNA will permanently inactivate Cas12a-crRNA complexes through a mode of inhibition not previously observed for any anti-CRISPR protein. However, we earlier demonstrated that AcrVA1 was not a robust inhibitor of ssDNA targeting by Cas12a (Fig. 1d and Supplementary Fig. 3) , which is at odds with the observed nuclease activity on the crRNA (Figs. 4a  and 5a ). We wondered whether the 5′ or 3′ fragments of the crRNA, together or separately, might still be sufficient for ssDNA targeting. To test this, we prepared RNA fragments that mimic products of AcrVA1 activity and assayed ssDNA targeting by LbCas12a. Remarkably, LbCas12a cleaved ssDNA in the presence of both the 5′ and 3′ fragments ( Supplementary Fig. 10c ), suggesting that the ssDNA targets can be recruited to Cas12a with a two-component crRNA. Taken together, our data demonstrate that AcrVA1 triggers crRNA truncation and release of the 3′ fragment from Cas12a, which can hybridize with a target ssDNA to activate cis-and transssDNA cleavage by Cas12a.
The ability of AcrVA1 to inhibit diverse Cas12a orthologs (Fig. 1c) suggested that it might exploit an evolutionarily conserved domain of Cas12a. To determine the domains required for AcrVA1-triggered spacer truncation, we generated truncations that still allowed for crRNA binding and pre-crRNA processing. Removal of either the PAM-interacting domain (PID) or both recognition (REC) domains generated stable constructs that maintained near wild-type mature crRNA binding affinity or pre-crRNA processing ( Supplementary Fig. 10b,c) . However, only in the absence of the PID was AcrVA1-triggered crRNA truncation prevented (Fig. 5b) . Finally, we wondered whether AcrVA4 or AcrVA5 might compete with the AcrVA1-triggered spacer truncation activity. To test this, we first incubated an LbCas12a RNP with either AcrVA4 or AcrVA5 before adding AcrVA1, and found that AcrVA5 reduced the rate of AcrVA1-triggered crRNA truncation (Fig. 5c) , suggesting that AcrVA5 does compete with the spacer truncation activity of AcrVA1.
Discussion
CRISPR-Cas12a are RNA-guided DNA-targeting nucleases with robust cis-cleavage and ssDNA trans-cleavage, activities that have led to their rapid implementation as tools for genome engineering and diagnostics 30 . In this work, we present mechanistic insights into type V-A bacteriophage-derived anti-CRISPRs elucidating the distinct modes leveraged to inactivate Cas12a (Fig. 6) . We found that AcrVA1, AcrVA4 and AcrVA5 robustly inhibited Cas12a dsDNA targeting, not unlike inhibitors that evolved to target Cas9 (ref. 8 ). AcrVA1 provides a uniquely potent mechanism for evading CRISPR adaptive immunity by triggering crRNA truncation with multiple-turnover kinetics to rapidly and permanently inactivate the Cas12a surveillance complex. We demonstrated that the nuclease activity is entirely dependent on the presence of a Cas12a-crRNA complex and AcrVA1, but our data do not describe the identity of the component bearing the catalytic center for the observed nuclease activity. Although it is probable that AcrVA1 is an RNase, we could not detect any RNase activity on free crRNA or trans-ssRNA substrates, suggesting that its activity is allosterically activated by binding to a Cas12a-crRNA complex or that Cas12a harbors the nuclease domain or a part thereof. AcrVA1 has a broad spectrum of inhibition, disabling divergent Cas12a nucleases in vitro and in mammalian cell editing 18 , potentially exploiting the broadly conserved PAM-interacting domain for direct access to the pre-ordered seed of the crRNA 31 . Interestingly, AcrVA1 displayed less robust inhibition of Cas12a ssDNA targeting, a potential artifact of working in vitro as the cleaved 3′ crRNA fragments can readily associate with ssDNA and be recruited back to Cas12a for activation. In the bacterial host, it is probable that cleavage of crRNA creates an ineffective two-component system. However, further experiments are required to determine whether AcrVA1 provides a selective advantage to ssDNA plasmids or ssDNA phages. It was recently shown that bacteriophages cooperate to immunocompromise bacterial hosts, delivering Acrs iteratively to gradually overcome CRISPR-Cas immunity 12, 13 . In light of these observations, bacteriophages encoding AcrVA1 may be the most effective in supporting populations of phage-lacking Acrs given its multiple-turnover kinetics, even with the recent data suggesting that Cas12a endonuclease activity can be reset 32 . Furthermore, Cas effectors are universally steered by programmable RNA guides, raising the possibility that all CRISPRCas systems are susceptible to this mode of inhibition. The unique mechanism for AcrVA1-mediated CRISPR-Cas12a inhibition may lend itself to potent control of Cas12a in gene-editing applications where it is desirable to block DNA targeting or limit unintended editing events.
We also found that AcrVA4 blocks dsDNA binding in addition to driving dimerization of Cas12a-crRNA complexes. This mechanism has also been described for AcrIIC3, which targets NmeCas9 (ref. 17 ). Although mechanistically and structurally divergent, Cas9 and Cas12a are susceptible to a convergent mechanism of inhibition suggesting that higher-order assembly of Cas nucleases and the associated inhibitors offers an as yet unclear benefit to bacteriophages. AcrVA4 was also able to disrupt a dLbCas12a-crRNA complex stably associated with dsDNA, an activity that required high concentrations of the inhibitor. The disruption of dLbCas12a dsDNA-bound states may have applicability in dLbCas12a-mediated transcriptional control applications, but further experiments are required to establish the off-rate for dsDNA in the presence of AcrVA4. Furthermore, while it is interesting to consider that AcrVA4 may shift the equilibrium in favor of dsDNA dissociation, this mode of action is unlikely to be biologically relevant, given that wild-type Cas12a rapidly catalyzes DNA cleavage once an R-loop is formed 29, 30 . Finally, we demonstrated that AcrVA5 robustly inhibited Cas12a dsDNA targeting activity by preventing dsDNA binding. Given that AcrVA5 competed with AcrVA1 and that AcrVA1 activity is dependent on the PID, we speculate that AcrVA5 may directly exploit the PID to block PAM recognition on dsDNA substrates. If true, this raises the possibility that AcrVA5 might be leveraged as a tool to block in vivo dsDNA targeting by Cas12a to exclusively select for ssDNA targeting. Furthermore, the panel of AcrVA tested in this study are more potent inhibitors of dsDNA targeting than ssDNA targeting by Cas12a, which may reflect an evolutionary pressure from dsDNA phages in the host's microbial community. Taken together, these mechanistic insights reveal vulnerabilities in the modes of Cas12a targeting, providing scope for greater control of a rapidly expanding landscape of Cas12a 33 complex, RNP was prepared at 40 nM effective concentration as described above before pre-forming a DNA-bound state with 32 P-dsDNA (0.1 nM) for 30 min at 37 °C. This was followed by the addition of AcrVA or cold DNA competitor (0 nM, 1 nM, 3 nM, 16 nM, 80 nM, 400 nM, 2 µM, 10 µM) for a further 30 min at 37 °C. To test ATP dependence, an excess of Cas12a (960 nM) was incubated with a titration of crRNA (0 pM, 2.4 pM, 9.7 pM, 39 pM, 0.156 nM, 0.625 nM, 2.5 nM, 10 nM, 40 nM, 160 nM, 640 nM) to pre-form the RNP for 30 min at 37 °C, before the addition of 32 P-dsDNA (0.1 nM) with or without 1 µM apyrase (NEB) or 2 µM ATP (NEB), and further incubation for 30 min at 37 °C. AcrVA4 (10 uM) was then introduced for a final incubation at 37 °C for 30 min. For all EMSAs, the resulting complexes were resolved by 6% (v/v) native PAGE (0.5× TBE supplemented with 5 mM MgCl 2 ) at 4 °C, visualized by phosphoroimaging (Amersham Typhoon, GE Healthcare) and quantified with ImageQuant (GE Healthcare). The fraction bound was determined as the ratio of intensity of the bound band relative to the total intensity of both the unbound band and the bound band, normalized to background and fit to a binding isotherm (Prism7, GraphPad) to calculate the dissociation constants (n = 3 independent experiments). Affinities and their associated standard deviations are reported in the Figure legends. Size-exclusion chromatography and coupled di-angle light scattering. All experiments were run in 20 mM HEPES.K (pH 7.5), 200 mM KCl, 1 mM TECP and 1 mM MgCl 2 on a Superdex 10/300 Increase column (GE Healthcare) at 0.5 ml min −1 using the Infinity 1260 Bio-SEC with light-scattering module (Agilent). Light scattering (LS) was collected at 15° and 90° using a 658 nm laser. The system was calibrated using a 2 mg ml -1 bovine serum albumin and refractive index increment (dn/dc) of 0.185 (ref. 41 ). Calibration constants were determined as: 280 nm ultraviolet = 567.9, LS 90° = 39,111.5 and LS 15° = 29,921.9. LS 15° data were not used in our calculations. Cas12a and AcrVA concentrations were determined by nanodrop before combination with nucleic acid substrates, and used as manual inputs for the mass calculation and a dn/dc of 0.185. All masses were determined using a first-degree fit over the linear region of mass estimates for each peak using the Bio-SEC software V A.02.01 (Agilent).
Single-particle negative-stain electron microscopy. Purified LbCas12a RNP bound to AcrA4 was prepared at ~50 nM and negatively stained in 2% (w/v) uranyl acetate (Electron Microscopy Sciences) solution following the standard deep-stain procedure on holey carbon-coated electron microscopy copper grids covered with a thin layer of continuous carbon. Negative-stained specimens were mounted on a transmission electron microscope holder and examined with a Tecnai Spirit electron microscope operated at 120 kV acceleration voltage. Magnified digital micrographs of the specimen were taken at a nominal magnification of ×51,000, on a Gatan Ultrascan4000 CCD camera with a pixel size of 2.18 Å, at the specimen level by Leginon 42 . The defocus values ranged from −0.9 to −1.5 μm, and the total accumulated dose at the specimen was about 60 electrons per Å 2 . Image analysis was performed in Appion 43 .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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